{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:36:36Z","timestamp":1790026596013,"version":"4.0.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01227-8","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T02:02:01Z","timestamp":1722564121000},"page":"2059-2075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of Epidermolysis Bullosa and Future Directions: A Review"],"prefix":"10.1007","volume":"14","author":[{"given":"Sorina","family":"Danescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mircea","family":"Negrutiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-507X","authenticated-orcid":false,"given":"Cristina","family":"Has","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"1227_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, et al. Epidermolysis bullosa. Nat Rev Dis Primer. 2020;6:78.","journal-title":"Nat Rev Dis Primer"},{"key":"1227_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183:614\u201327.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1227_CR3","doi-asserted-by":"publisher","first-page":"adv0053","DOI":"10.2340\/00015555-3398","volume":"100","author":"L Bruckner-Tuderman","year":"2020","unstructured":"Bruckner-Tuderman L. Skin fragility: perspectives on evidence-based therapies. Acta Derm Venereol. 2020;100(5):adv0053.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1227_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40257-021-00626-3","volume":"22","author":"PC Hou","year":"2021","unstructured":"Hou PC, Wang HT, Abhee S, Tu WT, McGrath JA, Hsu CK. Investigational treatments for epidermolysis bullosa. Am J Clin Dermatol. 2021;22(6):801\u201317.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1227_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.jid.2020.05.078","volume":"140","author":"JE Mellerio","year":"2020","unstructured":"Mellerio JE, Uitto J. Meeting report: the first global congress on epidermolysis bullosa, EB2020 London: toward treatment and cure. J Invest Dermatol. 2020;140(9):1681\u20137.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1227_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40291-020-00466-7","volume":"24","author":"C Has","year":"2020","unstructured":"Has C, South A, Uitto J. Molecular therapeutics in development for epidermolysis bullosa: update 2020. Mol Diagn Ther. 2020;24(3):299\u2013309.","journal-title":"Mol Diagn Ther"},{"issue":"19","key":"1227_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/TCRM.S386923","volume":"14","author":"PC Hou","year":"2023","unstructured":"Hou PC, Del Agua N, Lwin SM, Hsu CK, McGrath JA. Innovations in the treatment of dystrophic epidermolysis bullosa (DEB): current landscape and prospects. Ther Clin Risk Manag. 2023;14(19):455\u201373.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"1227_CR8","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/ijms25042243","volume":"25","author":"J Bischof","year":"2024","unstructured":"Bischof J, Hierl M, Koller U. Emerging gene therapeutics for epidermolysis bullosa under development. Int J Mol Sci. 2024;25(4):2243.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"1227_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Ba\u011fc\u0131 IS, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2211\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"1227_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","volume":"28","author":"I Gurevich","year":"2022","unstructured":"Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022;28(4):780\u20138.","journal-title":"Nat Med"},{"issue":"12","key":"1227_CR11","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1097\/MS9.0000000000001422","volume":"85","author":"A Khan","year":"2023","unstructured":"Khan A, Riaz R, Ashraf S, Akilimali A. Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa. Ann Med Surg (Lond). 2023;85(12):6298\u2013301.","journal-title":"Ann Med Surg (Lond)"},{"issue":"12","key":"1227_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.658295","volume":"30","author":"U Koller","year":"2021","unstructured":"Koller U, Bauer JW. Gene replacement therapies for genodermatoses: a status quo. Front Genet. 2021;30(12): 658295.","journal-title":"Front Genet"},{"issue":"7680","key":"1227_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","volume":"551","author":"T Hirsch","year":"2017","unstructured":"Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551(7680):327\u201332.","journal-title":"Nature"},{"key":"1227_CR14","doi-asserted-by":"crossref","unstructured":"Kueckelhaus M, Rothoeft T, De Rosa L, et al. Transgenic epidermal cultures for junctional epidermolysis bullosa\u20145-year outcomes. N Engl J Med. 2021;385(24):2264\u201370.","DOI":"10.1056\/NEJMoa2108544"},{"issue":"4","key":"1227_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.20910","volume":"186","author":"KS Subramaniam","year":"2022","unstructured":"Subramaniam KS, Antoniou MN, McGrath JA, Lwin SM. The potential of gene therapy for recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2022;186(4):609\u201319.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1227_CR16","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jid.2018.03.599","volume":"138","author":"M Marinkovich","year":"2018","unstructured":"Marinkovich M, Lane A, Sridhar K, Keene DR, Malyala A, Maslowski J. A phase 1\/2 study of genetically-corrected, collagen VII expressing autologous human dermal fibroblasts injected into the skin of patients with recessive dystrophic epidermolysis bullosa (RDEB). J Invest Dermatol. 2018;138(5):S100.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"1227_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126243","volume":"4","author":"SM Lwin","year":"2019","unstructured":"Lwin SM, Syed F, Di WL, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight. 2019;4(11): e126243.","journal-title":"JCI Insight"},{"issue":"6","key":"1227_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jid.2023.11.003","volume":"144","author":"G Conradt","year":"2024","unstructured":"Conradt G, Hausser I, Nystr\u00f6m A. Epidermal or dermal collagen VII is sufficient for skin integrity: insights to anchoring fibril homeostasis. J Invest Dermatol. 2024;144(6):1301\u20131310.e7.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1227_CR19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/bjd.18559","volume":"182","author":"S Gaucher","year":"2020","unstructured":"Gaucher S, Lwin SM, Titeux M, et al. EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I\/II gene therapy trial for recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2020;182(3):794\u20137.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1227_CR20","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/bjd.17943","volume":"181","author":"K Twaroski","year":"2019","unstructured":"Twaroski K, Eide C, Riddle MJ, et al. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2019;181(6):1247\u201353.","journal-title":"Br J Dermatol"},{"key":"1227_CR21","doi-asserted-by":"crossref","unstructured":"Matsumura W, Fujita Y, Shinkuma S, et al. Cultured epidermal autografts from clinically revertant skin as a potential wound treatment for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2019;139(10):2115\u20132124.e11.","DOI":"10.1016\/j.jid.2019.03.1155"},{"issue":"9","key":"1227_CR22","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3390\/biomedicines10092118","volume":"10","author":"PC van den Akker","year":"2022","unstructured":"van den Akker PC, Bolling MC, Pasmooij AMG. Revertant mosaicism in genodermatoses: natural gene therapy right before your eyes. Biomedicines. 2022;10(9):2118.","journal-title":"Biomedicines"},{"issue":"7","key":"1227_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/exd.14555","volume":"31","author":"EL Thompson","year":"2022","unstructured":"Thompson EL, Pickett-Leonard M, Riddle MJ, Chen W, Albert FW, Tolar J. Genes and compounds that increase type VII collagen expression as potential treatments for dystrophic epidermolysis bullosa. Exp Dermatol. 2022;31(7):1065\u201375.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1227_CR24","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2019.03.007","volume":"27","author":"J Bonafont","year":"2019","unstructured":"Bonafont J, Menc\u00eda \u00c1, Garc\u00eda M, et al. Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR\/Cas9-mediated gene editing. Mol Ther. 2019;27(5):986\u201398.","journal-title":"Mol Ther"},{"issue":"6","key":"1227_CR25","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.ymthe.2021.02.019","volume":"29","author":"J Bonafont","year":"2021","unstructured":"Bonafont J, Menc\u00eda A, Chac\u00f3n-Solano E, et al. Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing. Mol Ther. 2021;29(6):2008\u201318.","journal-title":"Mol Ther"},{"issue":"8","key":"1227_CR26","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.ymthe.2022.04.020","volume":"30","author":"J Bischof","year":"2022","unstructured":"Bischof J, March OP, Liemberger B, et al. Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa. Mol Ther. 2022;30(8):2680\u201392.","journal-title":"Mol Ther"},{"issue":"10","key":"1227_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292456","volume":"18","author":"TJ Sproule","year":"2023","unstructured":"Sproule TJ, Wilpan RY, Low BE, et al. Functional analysis of Collagen 17a1: a genetic modifier of junctional epidermolysis bullosa in mice. PLoS ONE. 2023;18(10): e0292456.","journal-title":"PLoS ONE"},{"issue":"1","key":"1227_CR28","doi-asserted-by":"publisher","first-page":"19643","DOI":"10.1038\/s41598-022-24184-8","volume":"12","author":"A Sheriff","year":"2022","unstructured":"Sheriff A, Guri I, Zebrowska P, et al. ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation. Sci Rep. 2022;12(1):19643.","journal-title":"Sci Rep"},{"issue":"2","key":"1227_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jid.2019.07.701","volume":"140","author":"MJ Osborn","year":"2020","unstructured":"Osborn MJ, Newby GA, McElroy AN, et al. Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. J Invest Dermatol. 2020;140(2):338\u201347.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1227_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-018-0834-2","volume":"13","author":"Y Shimizu-Motohashi","year":"2018","unstructured":"Shimizu-Motohashi Y, Murakami T, Kimura E, Komaki H, Watanabe N. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis. Orphanet J Rare Dis. 2018;13(1):93.","journal-title":"Orphanet J Rare Dis"},{"issue":"22","key":"1227_CR31","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.3390\/ijms222212222","volume":"22","author":"FC Vermeer","year":"2021","unstructured":"Vermeer FC, Bremer J, Sietsma RJ, et al. Therapeutic prospects of exon skipping for epidermolysis bullosa. Int J Mol Sci. 2021;22(22):12222.","journal-title":"Int J Mol Sci"},{"key":"1227_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2019.09.009","volume":"18","author":"J Bremer","year":"2019","unstructured":"Bremer J, van der Heijden EH, Eichhorn DS, et al. Natural exon skipping sets the stage for exon skipping as therapy for dystrophic epidermolysis bullosa. Mol Ther Nucleic Acids. 2019;18:465\u201375.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"1227_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jid.2020.08.018","volume":"141","author":"O Bornert","year":"2021","unstructured":"Bornert O, Hogervorst M, Nauroy P, et al. QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study. J Invest Dermatol. 2021;141(4):883-893. e6.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"1227_CR34","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.jid.2022.05.303","volume":"142","author":"A Bruckner","year":"2022","unstructured":"Bruckner A, Tang J, Chung W, et al. Collagen 7 (C7) protein replacement therapy (PTR-01) durably reduces wound size and symptoms in patients with recessive dystrophic epidermolysis bullosa (RDEB). J Invest Dermatol. 2022;142(8):S50.","journal-title":"J Invest Dermatol"},{"issue":"18","key":"1227_CR35","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMra1716145","volume":"380","author":"HM Blau","year":"2019","unstructured":"Blau HM, Daley GQ. Stem cells in the treatment of disease. N Engl J Med. 2019;380(18):1748\u201360.","journal-title":"N Engl J Med"},{"issue":"1","key":"1227_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/bmb\/ldaa029","volume":"136","author":"G Naso","year":"2020","unstructured":"Naso G, Petrova A. Cellular therapy options for genetic skin disorders with a focus on recessive dystrophic epidermolysis bullosa. Br Med Bull. 2020;136(1):30\u201345.","journal-title":"Br Med Bull"},{"issue":"2","key":"1227_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","volume":"83","author":"E Rashidghamat","year":"2020","unstructured":"Rashidghamat E, Kadiyirire T, Ayis S, et al. Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2020;83(2):447\u201354.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1227_CR38","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/bioengineering10040422","volume":"10","author":"A Niti","year":"2023","unstructured":"Niti A, Koliakos G, Michopoulou A. Stem cell therapies for epidermolysis bullosa treatment. Bioengineering (Basel). 2023;10(4):422.","journal-title":"Bioengineering (Basel)"},{"issue":"4","key":"1227_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15028","volume":"34","author":"F Shams","year":"2021","unstructured":"Shams F, Rahimpour A, Vahidnezhad H, et al. The utility of dermal fibroblasts in treatment of skin disorders: a paradigm of recessive dystrophic epidermolysis bullosa. Dermatol Ther. 2021;34(4): e15028.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1227_CR40","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/bjd.19503","volume":"184","author":"CL Ebens","year":"2021","unstructured":"Ebens CL, McGrath JA, Riedl JA, et al. Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds. Br J Dermatol. 2021;184(6):1161\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1227_CR41","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bjd.17858","volume":"181","author":"CL Ebens","year":"2019","unstructured":"Ebens CL, McGrath JA, Tamai K, et al. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts. Br J Dermatol. 2019;181(6):1238\u201346.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1227_CR42","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jcyt.2021.06.004","volume":"23","author":"J Riedl","year":"2021","unstructured":"Riedl J, Popp C, Eide C, Ebens C, Tolar J. Mesenchymal stromal cells in wound healing applications: role of the secretome, targeted delivery and impact on recessive dystrophic epidermolysis bullosa treatment. Cytotherapy. 2021;23(11):961\u201373.","journal-title":"Cytotherapy"},{"issue":"3","key":"1227_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2340\/00015555-3097","volume":"99","author":"KB Gosty\u0144ska","year":"2019","unstructured":"Gosty\u0144ska KB, Yenamandra VK, Lindemans C, et al. Allogeneic haematopoietic cell transplantation for epidermolysis bullosa: the Dutch experience. Acta Derm Venereol. 2019;99(3):347\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1227_CR44","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3390\/cells12111468","volume":"12","author":"E Niebergall-Roth","year":"2023","unstructured":"Niebergall-Roth E, Dieter K, Daniele C, et al. Kinetics of wound development and healing suggests a skin-stabilizing effect of allogeneic ABCB5+ mesenchymal stromal cell treatment in recessive dystrophic epidermolysis bullosa. Cells. 2023;12(11):1468.","journal-title":"Cells"},{"issue":"7","key":"1227_CR45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/stem.3356","volume":"39","author":"J Riedl","year":"2021","unstructured":"Riedl J, Pickett-Leonard M, Eide C, et al. ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment. Stem Cells. 2021;39(7):897\u2013903.","journal-title":"Stem Cells"},{"issue":"1","key":"1227_CR46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jid.2020.05.092","volume":"141","author":"Y Fujita","year":"2021","unstructured":"Fujita Y, Komatsu M, Lee SE, et al. Intravenous injection of muse cells as a potential therapeutic approach for epidermolysis bullosa. J Invest Dermatol. 2021;141(1):198-202.e6.","journal-title":"J Invest Dermatol"},{"issue":"22","key":"1227_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151922","volume":"6","author":"D Kiritsi","year":"2021","unstructured":"Kiritsi D, Dieter K, Niebergall-Roth E, et al. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. JCI Insight. 2021;6(22): e151922.","journal-title":"JCI Insight"},{"issue":"7","key":"1227_CR48","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jcyt.2023.01.015","volume":"25","author":"K Dieter","year":"2023","unstructured":"Dieter K, Niebergall-Roth E, Daniele C, et al. ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. Cytotherapy. 2023;25(7):782\u20138.","journal-title":"Cytotherapy"},{"issue":"10","key":"1227_CR49","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","volume":"21","author":"K O\u2019Brien","year":"2020","unstructured":"O\u2019Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020;21(10):585\u2013606.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"1227_CR50","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041227","volume":"14","author":"ER Bray","year":"2022","unstructured":"Bray ER, Kirsner RS, Badiavas EV. Mesenchymal stem cell-derived extracellular vesicles as an advanced therapy for chronic wounds. Cold Spring Harb Perspect Biol. 2022;14(10): a041227.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"1227_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230392","volume":"15","author":"T Goto","year":"2020","unstructured":"Goto T, Miyagawa S, Tamai K, et al. High-mobility group box 1 fragment suppresses adverse post-infarction remodeling by recruiting PDGFR\u03b1-positive bone marrow cells. PLoS ONE. 2020;15(4): e0230392.","journal-title":"PLoS ONE"},{"issue":"4","key":"1227_CR52","volume":"32","author":"A Schwieger-Briel","year":"2019","unstructured":"Schwieger-Briel A, Ott H, Kiritsi D, Laszczyk-Lauer M, Bodemer C. Mechanism of Oleogel-S10: a triterpene preparation for the treatment of epidermolysis bullosa. Dermatol Ther. 2019;32(4): e12983.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1227_CR53","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s12325-023-02749-x","volume":"41","author":"M Torres Pradilla","year":"2024","unstructured":"Torres Pradilla M, \u00c1lvarez E, Novoa M, Lozano I, Trujillo M. Oleogel-S10 in dystrophic epidermolysis bullosa: a case series evaluating the impact on wound burden over two years. Adv Ther. 2024;41(2):867\u201377.","journal-title":"Adv Ther"},{"issue":"1","key":"1227_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/bjd\/ljac001","volume":"188","author":"JS Kern","year":"2023","unstructured":"Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023;188(1):12\u201321.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1227_CR55","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13063-019-3362-z","volume":"20","author":"JS Kern","year":"2019","unstructured":"Kern JS, Schwieger-Briel A, L\u00f6we S, Sumeray M, Davis C, Martinez AE. Oleogel-S10 phase 3 study \u201cEASE\u201d for epidermolysis bullosa: study design and rationale. Trials. 2019;20(1):350.","journal-title":"Trials"},{"issue":"12","key":"1227_CR56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.25270\/wnds\/22-297299","volume":"34","author":"L Bolton","year":"2022","unstructured":"Bolton L. New options to manage epidermolysis bullosa. Wounds. 2022;34(12):297\u20139.","journal-title":"Wounds"},{"issue":"1","key":"1227_CR57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s13023-021-02062-2","volume":"16","author":"C Guttmann-Gruber","year":"2021","unstructured":"Guttmann-Gruber C, Pi\u00f1\u00f3n Hofbauer J, Tockner B, et al. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: a randomized, double-blind, placebo-controlled trial. Orphanet J Rare Dis. 2021;16(1):473.","journal-title":"Orphanet J Rare Dis"},{"key":"1227_CR58","doi-asserted-by":"crossref","unstructured":"Wally V, Reisenberger M, Kitzm\u00fcller S, Laimer M. Small molecule drug development for rare genodermatoses\u2014evaluation of the current status in epidermolysis bullosa. Orphanet J Rare Dis. 2020;15(1):292.","DOI":"10.1186\/s13023-020-01467-9"},{"issue":"10","key":"1227_CR59","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamadermatol.2023.2077","volume":"159","author":"GM Orlowski","year":"2023","unstructured":"Orlowski GM, Amano SU, Flanagan KE, Rieger KE, Marinkovich MP, Wiss K. Treatment with ataluren for wound healing and health complications in a patient with junctional epidermolysis bullosa. JAMA Dermatol. 2023;159(10):1145\u20137.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1227_CR60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000499906","volume":"235","author":"J Hammersen","year":"2019","unstructured":"Hammersen J, Neuner A, Wild F, Schneider H. Attenuation of severe generalized junctional epidermolysis bullosa by systemic treatment with gentamicin. Dermatology. 2019;235(4):315\u201322.","journal-title":"Dermatology"},{"issue":"6","key":"1227_CR61","doi-asserted-by":"publisher","first-page":"979","DOI":"10.5114\/ada.2020.97072","volume":"38","author":"K Osipowicz","year":"2021","unstructured":"Osipowicz K, Wychowanski P, Nieckula P, et al. Efficacy of gentamicin 0.3% solution of oral erosions healing in patients with severe generalized recessive dystrophic epidermolysis bullosa and its impact on the expression of type VII collagen. Postepy Dermatol Alergol. 2021;38(6):979\u201384.","journal-title":"Postepy Dermatol Alergol"},{"issue":"4","key":"1227_CR62","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1001\/jamadermatol.2021.5992","volume":"158","author":"D Mosallaei","year":"2022","unstructured":"Mosallaei D, Hao M, Antaya RJ, et al. Molecular and clinical outcomes after intravenous gentamicin treatment for patients with junctional epidermolysis bullosa caused by nonsense variants. JAMA Dermatol. 2022;158(4):366\u201374.","journal-title":"JAMA Dermatol"},{"key":"1227_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.02.027","author":"SB Saya","year":"2024","unstructured":"Saya SB, Has C. Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation. J Invest Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jid.2024.02.027.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1227_CR64","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/exd.14481","volume":"31","author":"A Onoufriadis","year":"2022","unstructured":"Onoufriadis A, Proudfoot LE, Ainali C, et al. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing. Exp Dermatol. 2022;31(3):420\u20136.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1227_CR65","doi-asserted-by":"publisher","first-page":"llad012","DOI":"10.1093\/ced\/llad012","volume":"48","author":"A Haghighi Javid","year":"2023","unstructured":"Haghighi Javid A, Li D, Technau-Hafsi K, Has C. IL-17A immune pattern across genetic acantholytic and blistering disorders. Clin Exp Dermatol. 2023;48(5):llad012.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1227_CR66","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14638","volume":"34","author":"J Uitto","year":"2021","unstructured":"Uitto J, Vahidnezhad H. Losartan for treatment of epidermolysis bullosa: a new perspective. Dermatol Ther. 2021;34(1): e14638.","journal-title":"Dermatol Ther"},{"issue":"7","key":"1227_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15515","volume":"35","author":"MR Pourani","year":"2022","unstructured":"Pourani MR, Vahidnezhad H, Mansouri P, Youssefian L, Rakhshan A, Hajimoradi B, Abdollahimajd F, Uitto J. Losartan treatment improves recessive dystrophic epidermolysis bullosa: a case series. Dermatol Ther. 2022;35(7): e15515.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1227_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15678","volume":"35","author":"M Relvas","year":"2022","unstructured":"Relvas M, Figueiredo AC, Calado R, Calv\u00e3o J, Ramos L, et al. Losartan as therapy for recessive dystrophic epidermolysis bullosa: report of three cases. Dermatol Ther. 2022;35(9): e15678.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1227_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14279","volume":"33","author":"AC Inamadar","year":"2020","unstructured":"Inamadar AC. Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa. Dermatol Ther. 2020;33(6): e14279.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1227_CR70","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/pharmaceutics14030570","volume":"14","author":"V Elezaj","year":"2022","unstructured":"Elezaj V, Lura A, Canha L, Breitkreutz J. Pharmaceutical development of film-coated mini-tablets with losartan potassium for epidermolysis bullosa. Pharmaceutics. 2022;14(3):570.","journal-title":"Pharmaceutics"},{"key":"1227_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.matbio.2018.12.001","volume":"81","author":"F Cianfarani","year":"2019","unstructured":"Cianfarani F, De Domenico E, Nystr\u00f6m A, et al. Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa. Matrix Biol. 2019;81:3\u201316.","journal-title":"Matrix Biol"},{"issue":"6","key":"1227_CR72","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/1346-8138.16729","volume":"50","author":"XG Wu","year":"2023","unstructured":"Wu XG, Yan S, Jiang JQ, et al. Successful treatment of epidermolysis bullosa pruriginosa by dupilumab. J Dermatol. 2023;50(6):837\u201342.","journal-title":"J Dermatol"},{"issue":"12","key":"1227_CR73","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1111\/ijd.16821","volume":"62","author":"J Xar\u00e1","year":"2023","unstructured":"Xar\u00e1 J, Relvas M, Figueiredo C, Calv\u00e3o J, Batista M. Ramos L Dupilumab in the treatment of dystrophic epidermolysis bullosa: off-label use in a pediatric patient. Int J Dermatol. 2023;62(12):e617\u20138.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1227_CR74","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ad.2022.05.045","volume":"115","author":"B Roque Quintana","year":"2024","unstructured":"Roque Quintana B, Piqu\u00e9 Dur\u00e1n E, P\u00e9rez Cejudo JA. Successful control of recalcitrant pruritus in epidermolysis bullosa pruriginosa with dupilumab. Actas Dermosifiliogr. 2024;115(2):184\u20136.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"1227_CR75","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/bjd.18855","volume":"182","author":"W Shehadeh","year":"2020","unstructured":"Shehadeh W, Sarig O, Bar J, Sprecher E, Samuelov L. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol. 2020;182(6):1495\u20137.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1227_CR76","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/pde.14493","volume":"38","author":"AG Zhou","year":"2021","unstructured":"Zhou AG, Little AJ, Antaya RJ. Epidermolysis bullosa pruriginosa treated with dupilumab. Pediatr Dermatol. 2021;38(2):526\u20137.","journal-title":"Pediatr Dermatol"},{"key":"1227_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15416","author":"S Gewert","year":"2024","unstructured":"Gewert S, Davidovic M, Has C, Kiritsi D. Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa. J Dtsch Dermatol Ges. 2024. https:\/\/doi.org\/10.1111\/ddg.15416.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"1227_CR78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/cge.14062","volume":"101","author":"F Chen","year":"2022","unstructured":"Chen F, Guo Y, Zhou K, et al. The clinical efficacy and safety of anti-IgE therapy in recessive dystrophic epidermolysis bullosa. Clin Genet. 2022;101(1):110\u20135.","journal-title":"Clin Genet"},{"issue":"3","key":"1227_CR79","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/1346-8138.17079","volume":"51","author":"IJ Kwon","year":"2024","unstructured":"Kwon IJ, Kim SE, Kim SC, Lee SE. Efficacy of oral JAK1 or JAK1\/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: a retrospective case series. J Dermatol. 2024;51(3):441\u20137.","journal-title":"J Dermatol"},{"issue":"6","key":"1227_CR80","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jaad.2019.09.014","volume":"82","author":"AS Chiou","year":"2020","unstructured":"Chiou AS, Choi S, Barriga M, et al. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: a randomized clinical trial. J Am Acad Dermatol. 2020;82(6):1415\u201321.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1227_CR81","first-page":"7","volume":"24","author":"AL Limmer","year":"2019","unstructured":"Limmer AL, Nwannunu CE, Shah R, Coleman K, Patel RR, Mui UN, Tyring SK. Topical diacerein ointment for epidermolysis bullosa simplex: a review. Skin Therapy Lett. 2019;24(3):7\u20139.","journal-title":"Skin Therapy Lett"},{"key":"1227_CR82","doi-asserted-by":"crossref","unstructured":"Teng J, Paller AS. Bruckner AL. Diacerein 1% ointment for the treatment of epidermolysis bullosa simplex: a randomized controlled trial. J Drugs Dermatol. 2023;22(6):599\u2013604.","DOI":"10.36849\/JDD.7108"},{"issue":"5","key":"1227_CR83","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1684\/ejd.2019.3642","volume":"29","author":"WS Yang","year":"2019","unstructured":"Yang WS, Kang S, Sung J, Kleinman HK. Thymosin \u03b24: potential to treat epidermolysis bullosa and other severe dermal injuries. Eur J Dermatol. 2019;29(5):459\u201367.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1227_CR84","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bjd.16897","volume":"180","author":"E Castela","year":"2019","unstructured":"Castela E, Tulic MK, Rozi\u00e8res A, et al. Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment. Br J Dermatol. 2019;180(2):357\u201364.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1227_CR85","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jid.2021.07.170","volume":"142","author":"GH Lee","year":"2022","unstructured":"Lee GH, Lekwuttikarn R, Tafoya E, Martin M, Sarin KY, Teng JM. Transcriptomic repositioning analysis identifies mTOR inhibitor as potential therapy for epidermolysis bullosa simplex. J Invest Dermatol. 2022;142(2):382\u20139.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1227_CR86","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/ijms23031732","volume":"23","author":"E Mayr","year":"2022","unstructured":"Mayr E, Ablinger M, Lettner T, et al. 5\u2019RNA trans-splicing repair of COL7A1 mutant transcripts in epidermolysis bullosa. Int J Mol Sci. 2022;23(3):1732.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1227_CR87","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.3390\/ijms24054341","volume":"24","author":"B Liemberger","year":"2023","unstructured":"Liemberger B, Bischof J, Ablinger M, et al. COL7A1 editing via RNA trans-splicing in RDEB-derived skin equivalents. Int J Mol Sci. 2023;24(5):4341.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1227_CR88","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13023-022-02546-9","volume":"17","author":"JY So","year":"2022","unstructured":"So JY, Nazaroff J, Iwummadu CV, et al. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):377.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01227-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01227-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:26:30Z","timestamp":1724081190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01227-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01227-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cristina Has has served as an advisor for Amryt Pharma and Krystal Biotech. Sorina Danescu and Mircea Negrutiu have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}